• Explore /
  • Poster
  • / Enzalutamide, docetaxel and androgen deprivation (ENZADA trial) for metastatic castrate sensitive prostate cancer (mCSPC).

Enzalutamide, docetaxel and androgen deprivation (ENZADA trial) for metastatic castrate sensitive prostate cancer (mCSPC).

Abstract Poster

Authors

null

Earle F Burgess

Levine Cancer Institute, Atrium Health, Charlotte, NC

Earle F Burgess , Claud Grigg , Danielle Boselli , Sarah Norek , Xhevahire J Begic , David L. Graham , James Thomas Symanowski , Derek Raghavan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Hormone-Sensitive

Clinical Trial Registration Number

NCT03246347

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 5072)

DOI

10.1200/JCO.2023.41.16_suppl.5072

Abstract #

5072

Poster Bd #

166

Abstract Disclosures

Similar Posters

First Author: Earle Frederick Burgess

First Author: Benjamin H. Lowentritt

First Author: Sachdev P. Thomas

First Author: Hirotsugu Uemura